Proteins and Peptides

22 July 2020

Dragonfly Therapeutics Initiates Phase 1/2 Study of its IL12 Immunotherapy in Patients with Advanced Solid Tumors

21 July 2020

Blue Earth Diagnostics Announces Dosing of Initial Patients in Phase 3 SPOTLIGHT Clinical Trial of Targeted PET Imaging Agent rhPSMA-7.3 (18F) in Biochemically Recurrent Prostate Cancer

21 July 2020

NeoImmuneTech Receives U.S. FDA Clearance of IND Application for Phase 2 Study of NT-I7 (efineptakin alfa) and Opdivo® (nivolumab)

21 July 2020

Pieris Pharmaceuticals Announces Partial Clinical Hold On PRS-343

21 July 2020

Biotest presented promising data on next generation recombinant Factor VIII at ISTH 2020

20 July 2020

Synairgen announces positive results from trial of SNG001 in hospitalised COVID-19 patients

20 July 2020

Bioniz announces positive efficacy and safety data for BNZ-1 from interim analysis of phase 1/2 study in cutaneous T-cell lymphoma

20 July 2020

Molecular Partners Provides Regulatory Update of European and Japanese Filings of Abicipar Pegol

14 July 2020

INmune Bio, Inc. Announces Interim Phase Ib Data Demonstrating That XPro1595 Decreases Neuroinflammation in Patients with Alzheimer’s Disease

10 July 2020

Atox Bio Announces a Positive Effect of Reltecimod on Resolution of Organ Dysfunction in Phase 3 ACCUTE Trial for Patients with Necrotizing Soft Tissue Infection (“Flesh Eating Disease”)

10 July 2020

FDA Approves Expanded BOTOX® (onabotulinumtoxinA) Label for the Treatment of Pediatric Patients with Spasticity

9 July 2020

Croma-Pharma announces submission for their botulinum toxin to treat glabellar (frown) lines to the German authority BfArM

8 July 2020

NextCure Initiates Phase 1/2 Clinical Study of NC410, a Novel Immunomedicine, for Solid Tumors

8 July 2020

Evive Biotech meets primary and secondary endpoints in global Phase III clinical trial for their novel chemotherapy-induced neutropenia treatment

7 July 2020

U.S. FDA Approves Qwo™ (collagenase clostridium histolyticum-aaes), the First Injectable Treatment for Cellulite

6 July 2020

EspeRare Receives FDA Breakthrough Therapy Designation for Investigational Prenatal Treatment ER-004 in X-Linked Hypohidrotic Ectodermal Dysplasia (XLHED)

6 July 2020

Insulin aspart Sanofi® receives EU marketing authorization, broadening options and increasing treatment choice for people with diabetes

1 July 2020

Rhythm Pharmaceuticals Announces Submission of Marketing Authorization Application to the European Medicines Agency for Setmelanotide in POMC and LEPR Deficiency Obesities

30 June 2020

Revance Announces Positive Results in Two Phase 2a Studies of DaxibotulinumtoxinA For Injection for the Treatment of Forehead Lines and Crow’s Feet, Respectively

30 June 2020

Vericel Announces Submission of Biologics License Application to the FDA for NexoBrid for the Treatment of Severe Thermal Burns

29 June 2020

Teijin Receives Marketing Approval for Merz’s Xeomin® Botulinum Toxin Type A in Japan

28 June 2020

Ascendis Pharma A/S Announces Submission of Biologics License Application (BLA) to FDA for TransCon™ hGH in Pediatric Growth Hormone Deficiency

28 June 2020

Chiasma Announces FDA Approval of MYCAPSSA® (Octreotide) Capsules, the First and Only Oral Somatostatin Analog

26 June 2020

NeoImmuneTech Announces First Patient Dosed in Phase 1b/2a Study of NT-I7 (efineptakin alfa) and KEYTRUDA® (pembrolizumab) in Patients with Relapsed/Refractory Advanced Solid Tumors

26 June 2020

Allergan, an AbbVie Company, and Molecular Partners Receive Complete Response Letter from FDA on Biologics License Application for Abicipar pegol

26 June 2020

Hansa Biopharma Receives Positive CHMP Opinion for IdefirixTM (imlifidase) for Kidney Transplant in EU

24 June 2020

Rhythm Pharmaceuticals Announces Positive Results from Phase 2 Study of Once-weekly Formulation of Setmelanotide in Healthy Obese Volunteers

24 June 2020

Simcha Therapeutics Launches to Engineer Therapeutic Cytokines to Unlock the Full Potential of the Immune System

24 June 2020

Zealand Pharma announces first patient dosed in Phase 2 trial with long-acting GLP-1/glucagon dual agonist in obesity/diabetes

23 June 2020

Ascendis Pharma A/S Announces Presentation of Preclinical Data for TransCon IL-2 β/γ at AACR Virtual Annual Meeting 2020

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

PSMA-Targeted Therapy Pipeline Review

PD-L1 x 4-1BB (CD137) Bispecific Antibody Pipeline Review

GPC3-Targeted Immunotherapy Pipeline Review

Degrader-Antibody Conjugates 2024: A Landscape Analysis of Stakeholders, Technologies, Pipeline and Partnering from an Industry Perspective

Claudin 6: A target opportunity to develop effector-enhanced drug modalities

CD40 Agonists & CD40/L Antagonists Pipeline Review

2020 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics

CD38-Targeted Antibody & Cell Therapy Pipeline Review

Blockbuster Biologics 2017: Sales of Recombinant Therapeutic Antibodies & Proteins

Eculizumab (Soliris) Biosimilars & Biosuperiors Pipeline Review